AVROBIO

We are a clinical-stage lentiviral gene therapy company, powered by our plato® gene therapy platform. Our vision: bring personalized gene therapy to the world.

[AVROBIO @avrobio]

Wishing everyone a wonderful #IndependenceDay!

[AVROBIO @avrobio]

Happy #CanadaDay! We hope that everyone recognizing the holiday today has a great time celebrating with family and friends.

[AVROBIO @avrobio]

#DYK #GaucherDisease (GD) is the most common #LysosomalDisorder?

It is a #GeneticDisease in which harmful amounts of fatty deposits accumulate in lysosomes, impairing cell function throughout the body.

Learn more: https://t.co/eYoEtKlca9

[AVROBIO @avrobio]

Our AVROBIO crewmates are on a mission to develop innovative #GeneTherapies to potentially revolutionize care for those living with #RareDiseases.

Check out our open positions: https://t.co/zcl3K8nuAH

[AVROBIO @avrobio]

Today our offices are closed in honor of #Juneteenth and we invite everyone to join us in reflecting on this important day in our history: https://t.co/7v9PvLP9DP

[AVROBIO @avrobio]

Build your knowledge of #GeneTherapy at https://t.co/IvLNuFveHi

#patients #PatientEducation #GeneTherapyEducation #RareDisease #genetics

[AVROBIO @avrobio]

Happy #PrideMonth! AVROBIO is proud to support the LGBTQ+ community and allies, especially those in #Biotech. Join us this June as we continue to foster inclusivity, diversity and kindness.

[AVROBIO @avrobio]

Our crewmates love #BlueBikes! AVROBIO provides each of our crewmates with a membership to get around #Boston.

[AVROBIO @avrobio]

We’ve assembled a team of multidisciplinary experts who are passionate about our purpose. Hear more about what makes AVROBIO special.

[AVROBIO @avrobio]

Today on #MPS Awareness Day we recognize those impacted by these metabolic disorders, specifically #MPSII, also known as #HunterSyndrome. We’re pleased that our collaborators at @OfficialUoM initiated a Phase 1/2 clinical trial in patients with Hunter syndrome.

[AVROBIO @avrobio]

Today is #cystinosis Awareness Day—we are recognizing everyone within the community, and specifically Jaxon and his family.

Learn about how his parents help him ensure his future by understanding his diagnosis and learning how to manage #cystinosis: https://t.co/sLl2apwZi0

[AVROBIO @avrobio]

#GeneTherapy is being discussed more and more these days. Want to learn about its significance? Let’s start at the foundation – our body’s cells!

Learn more by visiting: https://t.co/IvLNuFveHi

[AVROBIO @avrobio]

Earlier this week our AVROBIO crewmates celebrated #EarthDay by cleaning up our local neighborhood. Check out pictures from the event:

[AVROBIO @avrobio]

Today on #DNADay23 we are reflecting on how the discovery of the double helix structure started a genomic revolution that has enabled us to address #RareDisease at a DNA level.

Learn about AVROBIO’s investigational approach: https://t.co/MtxM6GxGIY

[AVROBIO @avrobio]

The National Organization for @RareDiseases #Running4Rare team participated in the BAA5k Run, and our AVROBIO crewmate Dennis Zimmermann proudly ran and fundraised with 11 team members. Congratulations and thanks for supporting the cause!

[AVROBIO @avrobio]

At AVROBIO, we are developing a new, single-dose approach that could potentially prevent the development of #MPSII, also known as #HunterSyndrome. Learn more: https://t.co/TqL9EgC9oF

[AVROBIO @avrobio]

Expand your knowledge of #GeneTherapy at https://t.co/IvLNuFveHi

#PatientEducation
#RareDisease
#Genetics

[AVROBIO @avrobio]

Today is #WorldHealthDay! We are working to achieve @WHO's vision of #HealthForAll by developing investigational gene therapies for people living with #RareDisesase including #GaucherDisease and #cystinosis. #WHO75

[AVROBIO @avrobio]

Advancing #GeneTherapy is important in every aspect of what we do at AVROBIO. Last month, our CEO @MackayGeo spoke at 6th Annual Gene Therapy for Rare Disorders about elevating safety and regulatory requirements of #GeneTherapy. Check out notable quotes from the event:

[AVROBIO @avrobio]

“#GaucherDisease is the largest, most common lysosomal disorder in the world, impacting an estimated 23,000 patients,” said MacKay. “AVROBIO is determined to develop a better solution for patients whose needs are not adequately addressed by the current standard of care.”

[AVROBIO @avrobio]

Recently our President and CEO @MackayGeo spoke about elevating #GeneTherapy safety at the Gene Therapy for Rare Disorders Summit. Read his latest blog to learn about 4 key variables that can impact safety and regulatory considerations: https://t.co/MvaWZAqjQn